Amarin Corporation Plc · NASDAQ:AMRN
Amarin — Q2 2026 Earnings Presentation
12 slides from Amarin's earnings presentation, July 2026
Slide 1: At the Heart of Improved Cardiovascular Outcomes
AT THE HEART OF IMPROVED CARDIOVASCULAR PLACEHOLDER FOR HERO IMAGE OUTCOMES Replace with licensed photography COMPANY OVERVIEW NASDAQ: AMRN | JULY 2026 AMARIN LOGO
Slide 2: Forward Looking Statements & Disclaimer
Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (icosapent ethyl) (VAZKEPA® in Europe and in other territories), clinical and regulatory efforts and timelines, potential regulatory and prici
Slide 3: A Message from our President & CEO
A Message from our President & CEO “Our results for Q2 2026 marked an inflection point in our evolution, demonstrating that the decisions we have made are translating into stronger execution, a scalable business model, and a path towards sustainable growth and profitability. We are seeing a promisin
Slide 4: Who We Are: An Established Leader in Cardiovascular Therapeutics
Who We Are: An Established Leader in Cardiovascular Therapeutics • First and only FDA-approved oral therapy to reduce cardiovascular (CV) risk when added to recommended statin therapy. • 2018 groundbreaking clinical study1 proved that VASCEPA® (icosapent ethyl or IPE) lowers the chance of a major ad
Slide 5: Where We Stand: Global Footprint, Refined Strategy and Solid Financial Position
Where We Stand: Leveraging a Global Footprint, Refined Strategy and Solid Financial Position; Poised for Long-Term Growth • Transformed international commercial strategy; fully partnered across nearly 100 countries; strategic emphasis on Europe supported by intellectual property protection through 2
Slide 6: Our Financials: Executing a More Efficient Operating Model
Our Financials: Executing a More Efficient Operating Model to Support Future Global Growth Key Takeaways: Operating Results: ($ in M) Q2 26 Q2 25 Change Q2 2026 Results Highlighted by Improved European Product Net Revenue $39.1 46.6 (16)% Sales from Q1 2026, Lower Operating Expenses, and U.S. Produc
Slide 7: Our U.S. Business: VASCEPA Remains U.S. Market Leader
Our U.S. Business: VASCEPA® Remains U.S. Market Leader Across All Available Icosapent Ethyl Products • Proven efficacy in CVRR • Refined U.S. commercial strategy providing efficient revenue generation and positive Quarterly U.S. Prescription Growth v. Prior Year Period cash flow • Based on early fee
Slide 8: Our International Business: Syndicate of Established Partners
Our International Business: Maximizing Ex-U.S. Access Through a Syndicate of Established Partners CANADA EUROPE Commercialization efforts New exclusive license & supply progressing agreement CHINA CVRR approval secured; Focus on Private Pay Market SOUTH KOREA AND ASEAN South Korea and Singapore regu
Slide 9: Recordati Partnership Advancing VAZKEPA's European Growth Opportunity
Our International Business: Recordati Partnership Advancing VAZKEPA’s European Growth Opportunity Why We Partnered One Year of Progress Long-Term Value Creation Unlock the full European Execution translating into commercial Amarin Future Opportunity opportunity momentum Favorable Economics o Exclusi
Slide 10: Seven Partners Actively Building Market Opportunities
Our International Business: Seven Partners Actively Building Market Opportunities Across Multiple Continents 7 Ex-U.S. partnerships focused on maximizing patient access to VASCEPA/ Regulatory Pricing & Reimbursement: VAZKEPA – many in early commercialization stages, poised for future growth. o Worki
Slide 11: 2H 2026 Focus: Continued Execution & Driving Long-term Growth
2H 2026 Focus: Continued Execution & Driving Long-term Growth Opportunities A multi-pronged and multi-national approach: • Accelerate commercial expansion across partnered international markets to maximize patient access. • Sustain U.S. leadership in the branded IPE market. • Maintain disciplined fi
Slide 12: Amarin Key Takeaways
Amarin Key Takeaways HEALTHY FINANCIALS UNTAPPED POTENTIAL PRODUCT POWER STRONG SCIENCE MEDICAL ENDORSEMENT Cash Flow ~640M >271K 3 500+ PEOPLE LIVING WITH CVD, EXPECT TO BE CASH FLOW MAKING IT THE LEADING CAUSE U.S. PRESCRIBERS SUCCESSFUL PHASE 3 SCIENTIFIC PUBLICATIONS POSITIVE FOR FULL YEAR 2026